$1.0 SP by Xmas. Cheap now at 22CentsAgenix CEO and Managing...

$1.0 SP by Xmas. Cheap now at 22Cents

Agenix CEO and Managing Director, Mr. Neil Leggett, stated: “The distribution
arrangement with Sinopharm is an important step in YouHeDing’s sales and
marketing rollout. However, Agenix Bio-Pharmaceutical (Shanghai) CEO, Mr.
Jonathan Zhang, and his team are doing an outstanding job in establishing our direct
sales force in China, which is the main method we will adopt to sell our drug. We are
projecting that revenue from YouHeDing will rise to over RMB320 million (A$47.2
million) per annum as the sales and marketing network is rolled out over the next few
years.”
“The potential market for our drug is huge. China has over 130 million HBV carriers
and 30 million – 40 million chronic HBV patients,” Mr. Leggett said.
Agenix announced, on 02 October 2007, that a New Drug Approval for YouHeDing
was received from the State Food and Drug Administration of the People’s Republic
of China (“SFDA).
END
For more information